NEW YORK (GenomeWeb News) — GenOway will supply “a leading” but undisclosed US pharmaceutical company with its genetically modified mouse lines in exchange for up to $2 million, the firm said yesterday.
 
GenOway makes a line of genetically modified mouse and rat lines, and uses knowledge in transgenic technologies including pronuclear microinjection, knock-out, knock-in, knock-down, point mutation, in vivo drug screening, drug efficacy, and safety testing.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.